라니티딘을 함유한 새로운 위장질환 치료용 의약조성물(DWP302)의 약물동태

• 영문명: Pharmacokinetics of DWP302, a New Combined Ranitidine Preparations for Gastroduodenal Diseases
• 발행기관: 대한약학회
• 저자명: 김영만(Young Man Kim) 김동오(Dong O Kim) 김영도(Young Do Kim) 남권호(Kweon Ho Nam) 이성원(Sung Won Lee) 이주헌(Joo Hun Lee) 김학형(Hak Kyoung Kim) 유영효(Young Hyo Yu) 박명환(Myung Hwan Park)
• 간행물 정보: 『약학회지』제37권 제5호 (1993년), 544~548쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 1993.10.30

영문 초록

The pharmacokinetics of DWP302, a new combined ranitidine preparation in rats and dogs was studied using HPLC. DWP302 was composed of ranitidine, sucralfate and tripotassium dicitrato bismuthate. Especially, this study was focused on the possibilities that the concomitant administration of either sucralfate or TDB may affect the absorption of orally administered ranitidine. Ranitidine and DWP302 were orally administered to rats at a dose of ranitidine 10mg/kg. Several rats showed the biphasic peak of plasma concentration. AUCs0-8 of ranitidine and DWP302 group were found to be 1040 +/- 109 and 945 +/- 124ng.hr/ml, respectively, and there was no significant difference between both AUCs. In a cross-over study for dogs, Cmax t1/2 beta and total AUC of ranitidine group were found to be 625.8 +/- 86.7ng/ml, 2.80 +/- 0.28 hr and 1688 +/- 127ng.hr/ml, and those of DWP302 group were 562.6 +/- 120.9ng/ml, 3.05 +/- 0.30 hr and 1673 +/- 123ng.hr/ml, respectively. There was no significant difference between those parameters, but Tmax of DWP302 group (1.69 +/- 0.31 hr) was significantly different from ranitidine group (1.13 +/- 0.26 hr). The results suggest that either sucralfate or TDB may affect the lag-time or rate of absorption of ranitidine but not the extent of absorption.

키워드

Ranitidine DWP302 tripotassium dicitrato bismuthate(TDB) sucralfate pharmacokinetics rat dog absorption plasma.